Dr. Scheer brings over 25 years of international life science experience in multiple disciplines, technologies and therapeutic areas Leuven, BELGIUM – 23 April 2020 – Aelin Therapeutics NV, an emerging…
Aelin Therapeutics will be attending the Novel Antimicrobials and AMR Diagnostics meeting in Berlin.
Please join Els Beirnaert, CEO, presenting on Friday March 15thhttps://amr-conference.com/home/
Els Beirnaert, CEO van Aelin Therapeutics in Z-talk https://kanaalz.knack.be/talk/als-we-niet-snel-ingrijpen-worden-standaardingrepen-binnenkort-problematisch-22-12-18/video-normal-1409969.html
The young biotech spin-off gains momentum with a VLAIO grant and an investor award Aelin Therapeutics announced today that it has been awarded close to 1M EUR in non-dilutive funding…
Yesterday at the Jefferies 2018 London Healthcare Conference, Aelin Therapeutics has been awarded the Life Stars award for EU Private Finance Raise of the year. The Jefferies conference is the largest…
Researchers at VIB, KU Leuven and UZ Leuven devised a novel approach to develop antibacterial drugs. With antibiotic resistance on the rise worldwide, such new drugs are urgently needed. The…
Aggregation is a sequence-specific process, nucleated by short aggregation-prone regions (APRs) that can be exploited to induce aggregation of proteins containing the same APR. Here, we find that most APRs…
New VIB start-up Aelin Therapeutics secures 27 M€ to exploit its proprietary Pept-in™ protein knockdown platform Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured…
Amyloid aggregation is driven by short sequences within proteins that self-assemble into characteristic amyloid structures. About 30 human proteins are implicated in amyloid-associated diseases, but many more contain short sequences…
Dr. Scheer brings over 25 years of international life science experience in multiple disciplines, technologies and therapeutic areas Leuven, BELGIUM – 23 April 2020 – Aelin Therapeutics NV, an emerging…
Aelin Therapeutics will be attending the Novel Antimicrobials and AMR Diagnostics meeting in Berlin.
Please join Els Beirnaert, CEO, presenting on Friday March 15thhttps://amr-conference.com/home/
Els Beirnaert, CEO van Aelin Therapeutics in Z-talk https://kanaalz.knack.be/talk/als-we-niet-snel-ingrijpen-worden-standaardingrepen-binnenkort-problematisch-22-12-18/video-normal-1409969.html
The young biotech spin-off gains momentum with a VLAIO grant and an investor award Aelin Therapeutics announced today that it has been awarded close to 1M EUR in non-dilutive funding…
Yesterday at the Jefferies 2018 London Healthcare Conference, Aelin Therapeutics has been awarded the Life Stars award for EU Private Finance Raise of the year. The Jefferies conference is the largest…
Researchers at VIB, KU Leuven and UZ Leuven devised a novel approach to develop antibacterial drugs. With antibiotic resistance on the rise worldwide, such new drugs are urgently needed. The…
New VIB start-up Aelin Therapeutics secures 27 M€ to exploit its proprietary Pept-in™ protein knockdown platform Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured…
Aggregation is a sequence-specific process, nucleated by short aggregation-prone regions (APRs) that can be exploited to induce aggregation of proteins containing the same APR. Here, we find that most APRs…
Amyloid aggregation is driven by short sequences within proteins that self-assemble into characteristic amyloid structures. About 30 human proteins are implicated in amyloid-associated diseases, but many more contain short sequences…
Taking advantage of the xenobiotic nature of bacterial infections, we tested whether the cytotoxicity of protein aggregation can be targeted to bacterial pathogens without affecting their mammalian hosts. In particular,…
